3-bromo-propylcarbamic acid butyl ester | 18678-11-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-bromo-propylcarbamic acid butyl ester
• 英文别名: 3-butoxycarbonylaminopropyl bromide；butoxycarbonyl-3-bromopropylamine；butoxycarbonylaminopropyl bromide；BUTYL N-(3-BROMOPROPYL)CARBAMATE；butyl 3-bromopropylcarbamate
• CAS: 18678-11-0
• 化学式: C₈H₁₆BrNO₂
• 分子量: 238.125
• InChiKey: YVVMKHVRAIYTEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NEW ANTIBACTERIAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS
  申请人：ACRAF

  公开号：WO2016096631A1

  公开（公告）日：2016-06-23

  The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

  本发明涉及新型的抗菌化合物、含有它们的药物组合物以及它们作为抗菌剂的应用。
• [EN] PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS PROTÉINE-MACROMOLÉCULE ET LEURS MÉTHODES D'UTILISATION
  申请人：BEIJING XUANYI PHARMASCIENCES CO LTD

  公开号：WO2021067458A1

  公开（公告）日：2021-04-08

  The present disclosure provides protein-macromolecule conjugates, releasable linkers, and macromolecules, as defined herein. The disclosed conjugates provide unique properties that are based at least upon the properties of linker and number of linker-Macromolecule moieties. Also provided herein are a method of synthesis and use of conjugates in treating diseases and disorders.

  本公告提供了蛋白质-大分子共轭物、可释放连接剂和大分子，如本文所定义。所公开的共轭物提供了基于连接剂属性和连接剂-大分子基团数量的独特性质。本文还提供了一种合成方法和在治疗疾病和紊乱中使用共轭物的方法。
• 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
  申请人：PFIZER INC.

  公开号：EP0997464A1

  公开（公告）日：2000-05-03

  A compound of the formula: R1 and R2 are independently C1-C4 alkyl; or R1 and R2, taken together with the carbon atom to which they are attached, form a mono-, bi-, tri- or spiro-cyclic group having 3 to 13 carbon atoms, wherein the cyclic group is optionally substituted by one to five substituents; A is (C1-C3)alkyl, phenyl, benzyl or the like; R is hydrogen, (C1-C3)alkyl, amino-(C1-C6)alkyl, heterocyclic-(C1-C3)alkyl wherein the heterocyclic is optionally substituted by amino, ((C1-C4)alkyl)-Z-(C1-C6)alkyl wherein Z is OC(=O) or the like; and X is (C1-C3)alkyl, phenyl or the like. These compounds are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.

  式中的化合物： R1 和 R2 独立地为 C1-C4 烷基；或 R1 和 R2 与它们所连接的碳原子一起，形成具有 3 至 13 个碳原子的单环、双环、三环或螺环基团，其中环基团任选被 1 至 5 个取代基取代；A是(C1-C3)烷基、苯基、苄基或类似物；R是氢、(C1-C3)烷基、氨基-(C1-C6)烷基、杂环-(C1-C3)烷基（其中杂环任选被氨基取代）、((C1-C4)烷基)-Z-(C1-C6)烷基（其中 Z 是 OC(=O) 或类似物）；X是(C1-C3)烷基、苯基或类似物。这些化合物可用作 ORL1 受体激动剂，也可用作哺乳动物的镇痛剂或类似药物。
• 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS
  申请人：PFIZER INC.

  公开号：EP1102762A2

  公开（公告）日：2001-05-30
• NEW ANTIBACTERIAL COMPOUNDS
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP3233826A1

  公开（公告）日：2017-10-25